Gaudium IVF Share Price Down 16.48% As Q3 Profit Declines Sharply, Margin Pressure Evident

Mumbai, March 19: Share price of Gaudium IVF and Women Health Limited fell 16.48% to ₹79.16 as of 2:39 PM IST on Thursday, compared with the previous close of ₹94.78. The stock witnessed sustained selling pressure through the session, hitting a low of ₹78.50 so far, after the company reported its December quarter financial results.

The decline followed the company’s disclosure to exchanges on March 18, 2026, where it announced its unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025.

Why The Share Price Moved

The sharp drop in profitability appears to have weighed on investor sentiment. Net profit for the quarter stood at ₹318.40 lakh, significantly lower than ₹902.54 lakh reported in the preceding September quarter.

Revenue from operations came in at ₹1,419.35 lakh, down from ₹2,294.58 lakh sequentially. While year-on-year revenue was marginally higher versus ₹1,394.66 lakh, the steep sequential decline, coupled with rising cost pressures, likely triggered the sell-off.

Expenses remained elevated across key heads. Employee benefit expenses rose to ₹206.87 lakh, while finance costs increased to ₹112.26 lakh, reflecting higher operational and funding costs. Total expenses stood at ₹995.06 lakh, compressing operating margins.

Stock Performance Snapshot

The stock opened at ₹82.51 on March 19, 2026, and touched a high of ₹85.79 before sliding through the session. It is currently trading closer to its day’s low, indicating persistent selling pressure.

On a broader scale, the stock remains well below its 52-week high of ₹99.75, though still above the 52-week low of ₹72.02. The company’s market capitalisation stands at approximately ₹576.84 crore.

What This Means For Investors

The sequential decline in both revenue and profitability signals potential demand moderation or operational challenges in the core healthcare services segment.

That said, the company continues to remain profitable on a year-on-date basis, reporting net profit of ₹1,455.64 lakh for the nine months ended December 31, 2025, compared with ₹1,242.46 lakh in the corresponding period last year. This indicates underlying business continuity, even as quarterly volatility persists.

Investors may closely track margin trends and revenue recovery in upcoming quarters, particularly after the company’s recent listing.

Broader Market And Sectoral Context

The reaction also comes amid heightened scrutiny of newly listed healthcare and SME segment stocks, where earnings visibility and consistency are key valuation drivers.

Notably, Gaudium IVF completed its IPO and listed on exchanges on February 27, 2026. Stocks in the post-listing phase often witness sharper price discovery, especially around initial earnings disclosures.

In contrast, the broader healthcare sector has remained relatively stable, suggesting the decline is largely company-specific rather than sector-driven.

About The Company

Gaudium IVF and Women Health Limited operates in the healthcare services segment, focusing on fertility treatments and women’s health services.

The company reported that its financial results for the quarter ended December 31, 2025, were reviewed by S K G N & Associates LLP, which issued an unmodified limited review report under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conclusion

The sharp correction in the stock reflects investor concerns over sequential earnings pressure and margin compression following the latest quarterly results. While year-to-date performance remains stable, near-term sentiment appears tied to the company’s ability to stabilise revenue growth and manage costs in the coming quarters.

Source:

• https://www.nseindia.com/get-quote/equity/GAUDIUMIVF/Gaudium-IVF-and-Women-Health-Limited
• https://nsearchives.nseindia.com/corporate/GAUDIUM_18032026184834_UFR_Gaudium_IVF_Signed.pdf